History
History
2021
- Completed phase 3 clinical trial of Botulinum Toxin Type A Formulation (BCD200)
2020
- Acquired permit for export of 200 Units Re N Tox
- Granted approval of phase 3 IND clinical trial of Botulinum Toxin Type A Formulation (BCD200)
- Completed phase 1 clinical trial of Botulinum Toxin Type A Formulation (BCD200)
2019
- Concluded license agreement of Botulinum Toxin Type A Product
(LG Chem) - Started exporting Re N Tox overseas
- Acquired permit for export of 100 Units Re N Tox
- Acquired GMP certification for Gangneung Factory
- Acquired permit for phase 1 IND clinical trial of Botulinum Toxin Type A Formulation (BCD200)
2018
- Acquired permit to manufacture drugs for Gangneung Factory
- Changed company name to PharmaResearch BIO Co., Ltd.
2017
- Completed plant construction
- Completed preclinical trial of Botulinum Toxin
2016
- Initiated the construction of Botulinum Toxin plant
2015
- Listed in KONEX
- Established a research institute in Gangneung Science Industrial Complex
2010
- Provided consulting services for biopharmaceutical development such as EPO, hepatitis B vaccine, recombinant protein, etc.
2009
- Established BIOCND Co., Ltd.